CRSP is trading 4.2% up at $57.25 amid a broadly bullish market backdrop and positive sentiment toward gene-editing names.
- Major U.S. indices are trading up around 1%, driving a risk-on appetite that has benefited the broader biotech sector.
- Traders are bidding the stock higher following recent analyst reports highlighting the company as deeply undervalued.
- The upward move occurs without a specific new company announcement, suggesting momentum is driven by market-wide factors.